| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues: |
| Shared Services and Other | | | | | | | 11.9 | |
| Other | | | 279.8 | 264.6 | | | 196.0 | 207.1 |
| Total revenues | 338.1 | 320.7 | 299.5 | 285.7 | 276.5 | 268.2 | 259.9 | 268.0 |
| Revenue growth [+] | 22.3% | 19.6% | 15.3% | 6.6% | 2.2% | -5.3% | -12.6% | -8.6% |
| CareVention HealthCare | | | | | | | 20.2% | 19.9% |
| Cost of goods sold | 258.3 | 247.4 | 232.6 | 220.2 | 211.1 | 202.1 | 193.4 | 198.6 |
| Gross profit | 79.8 | 73.3 | 66.9 | 65.6 | 65.4 | 66.1 | 66.5 | 69.4 |
| Gross margin | 23.6% | 22.9% | 22.3% | 22.9% | 23.6% | 24.6% | 25.6% | 25.9% |
| Selling, general and administrative [+] | 89.0 | 86.0 | 85.5 | 86.8 | 73.1 | 75.0 | 74.1 | 76.4 |
| Sales and marketing | 10.9 | 10.3 | 10.5 | 10.5 | 10.4 | 10.7 | 11.0 | 14.2 |
| General and administrative | 78.1 | 75.7 | 75.0 | 76.3 | 62.8 | 64.3 | 63.1 | 62.2 |
| Research and development | 10.3 | 11.8 | 14.5 | 14.8 | 14.5 | 15.5 | 14.6 | 15.5 |
| Other operating expenses | 7.4 | 4.0 | 3.7 | | | | | |
| Adjusted EBITDA | -0.1 | 2.2 | 7.5 | 20.3 | 31.7 | 41.7 | 43.4 | 39.5 |
| Adjusted EBITDA margin | 0.0% | 0.7% | 2.5% | 7.1% | 11.5% | 15.6% | 16.7% | 14.7% |
| Stock-based compensation | 26.8 | 30.7 | 36.8 | 42.0 | 32.8 | 38.5 | 38.5 | 39.1 |
| EBITDA [+] | -26.9 | -28.5 | -29.4 | -21.7 | -1.1 | 3.3 | 5.0 | 0.4 |
| EBITDA growth | 2263.1% | -971.1% | -691.2% | -5449.3% | -87.0% | -138.5% | -139.1% | -105.2% |
| EBITDA margin | -7.9% | -8.9% | -9.8% | -7.6% | -0.4% | 1.2% | 1.9% | 0.2% |
| Depreciation | 17.6 | 16.9 | 23.6 | 29.7 | 35.9 | 41.8 | 40.1 | 33.7 |
| EBITA | -44.4 | -45.4 | -53.0 | -51.5 | -37.0 | -38.5 | -35.2 | -33.3 |
| EBITA margin | -13.1% | -14.2% | -17.7% | -18.0% | -13.4% | -14.4% | -13.5% | -12.4% |
| Amortization of intangibles | 6.8 | 6.9 | 7.0 | 6.9 | 7.1 | 7.3 | 7.6 | 14.4 |
| EBIT [+] | -51.3 | -52.3 | -60.0 | -58.4 | -44.2 | -45.9 | -42.7 | -47.7 |
| EBIT growth | 16.1% | 14.1% | 40.5% | 22.5% | -22.4% | -17.0% | -26.0% | -4.4% |
| EBIT margin | -15.2% | -16.3% | -20.0% | -20.4% | -16.0% | -17.1% | -16.4% | -17.8% |
| Non-recurring items [+] | | | 8.9 | | | 4.1 | | |
| Asset impairment | | | 8.9 | | | 4.1 | | |
| Interest expense | 6.7 | 8.0 | 9.0 | 9.6 | 9.1 | 8.8 | 9.1 | 13.7 |
| Interest expense | 6.7 | 8.0 | 9.0 | 9.6 | 9.1 | 8.8 | 9.1 | 13.7 |
| Other income (expense), net [+] | 2.1 | 1.5 | 1.1 | 0.5 | | | | |
| Other | 2.1 | 1.5 | 1.1 | 0.5 | | | | |
| Pre-tax income | -60.8 | -63.7 | -76.9 | -71.5 | -57.3 | -58.8 | -51.8 | -69.0 |
| Income taxes | 0.3 | 0.3 | 0.4 | 0.5 | 0.6 | 0.5 | 0.4 | 0.8 |
| Tax rate | | | | -0.7% | | | | |
| Earnings from continuing ops | -61.1 | -64.0 | -77.3 | -72.0 | -57.9 | -59.3 | -52.2 | -69.8 |
| Earnings from discontinued ops | | -34.3 | -33.3 | -30.3 | | -28.5 | -26.8 | -18.5 |
| Net income | -95.5 | -135.2 | -147.5 | -139.2 | -116.3 | -87.8 | -79.1 | -88.3 |
| Net margin | -28.2% | -42.2% | -49.2% | -48.7% | -42.1% | -32.7% | -30.4% | -32.9% |
| |
| Basic EPS [+] | ($2.46) | ($2.62) | ($3.21) | ($3.02) | ($2.45) | ($2.53) | ($2.25) | ($3.05) |
| Growth | 0.4% | 3.6% | 42.7% | -1.2% | -30.9% | -30.3% | -40.0% | 13.9% |
| Diluted EPS [+] | ($2.46) | ($2.62) | ($3.21) | ($3.02) | ($2.45) | ($2.53) | ($2.25) | ($3.05) |
| Growth | 0.4% | 3.6% | 42.7% | -1.2% | -30.9% | -30.3% | -40.0% | 13.9% |
| |
| Shares outstanding (basic) [+] | 24.8 | 24.5 | 24.1 | 23.9 | 23.6 | 23.5 | 23.2 | 22.9 |
| Growth | 5.1% | 4.3% | 3.8% | 4.3% | 5.2% | 6.4% | 7.5% | 7.2% |
| Shares outstanding (diluted) [+] | 24.8 | 24.5 | 24.1 | 23.9 | 23.6 | 23.5 | 23.2 | 22.9 |
| Growth | 5.1% | 4.3% | 3.8% | 4.3% | 5.2% | 6.4% | 7.5% | 7.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |